Aims of the Call
The main purpose of this call will be design of patient preclinical models for combination therapies. Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients.
Proposals will have to cover only one of the three specific aims listed below. Approaches should be directed to obtain a portfolio of renewed methods for new efficacious combination therapy strategies. Projects should be built from a solid and established hypothesis and should be relevant regarding the potential improvements in clinical practice.
Specific aims
- Development of new tumour derived models to test new drug combination therapies
- Design and development of high-throughput drug combination screening platforms to test new combination therapies
- Use of immunotherapy and radiotherapy combinations strategies to overcome drug resistance
Capacity building activities
Applicants may also request funding for capacity building activities. Capacity building activities have to be fully coherent with the objectives of the research project and aimed at strengthening the ability of participating teams to perform the work detailed in the project plan as well as to improve, in the long term, the quality and potential of the translational research performed by the teams.
Eligibility
- Only transnational projects will be funded.
- Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners eligible for funding, coming from different countries whose funders participate in the call.
- The partners must be from at least three (3) different countries participating in the call.
- It is mandatory to integrate at least one early-career researcher (ECR) as principal investigator in a consortium and this has to be clearly indicated in the proposal.
- Each consortium must involve at least one basic or pre-clinical research team and one clinical team. It is also recommended to include an expert team in methodology, biostatistics or bioinformatics, depending on the type of work planned.
Applicants should refer to the annexes of the document “Guidelines for Applicants” containing all the specific national/regional eligibility criteria and should contact their respective national/regional funding organisation contact points for additional clarification
Funding
The Norwegian sponsors of this call are Research Council Norway and the Norwegian Cancer Society. The anticipated number of fundable projects with Norwegian participation is 2-4.
Funding per grant is 300.000 Euro for Norwegian partners pr project and 400.000 Euro for project coordinators.
Additional information
Prospective applicants are advised to read the full call e on ERA-NET TRANSCAN-3 website.
In addition, Research Council Norway provides some information to Norwegian applicants.
Contact
Transcan-3 Joint call secretariat, TRANSCAN_JTC2024@isciii.es
Tine Thorbjørnsen, Researh Council of Norway, tth@forskningsradet.no